AI demand lifts Twist, but price matters
- Q3 FY26 revenue rose 23.2% to $118.4 million, showing continued strong demand.
- DNA synthesis and protein solutions grew 39%, driven by AI-enabled drug discovery.
- NGS applications grew 12% year over year, with investors watching for a stronger re-acceleration.
- Management expects triple-digit order growth in AI discovery to extend into fiscal 2027.
- The setup is still hard due to high expectations, ongoing investment, and a very demanding valuation.
Growth is real, expectations are high
Twist's latest quarter confirmed its top-line momentum. Q3 FY26 revenue grew 23.2% to $118.4 million. DNA synthesis and protein solutions accelerated to 39% growth, while NGS applications grew 12%. The bull case is anchored by the company capturing demand from AI-enabled drug discovery, turning it into a sustainable growth engine.
The AI story is maturing rapidly. Management expressed increased confidence in achieving triple-digit percentage order growth for AI-enabled discovery in fiscal 2026 and expects this to continue into early fiscal 2027. This suggests customers are integrating Twist's platform deeply into their workflows.
The bear case centers on execution risk and valuation. As Twist aggressively scales its DNA synthesis segment, gross margin slightly compressed to 52.8% in Q3 due to customer mix. The company is targeting adjusted EBITDA breakeven by Q4 FY26. If the NGS business fails to re-accelerate or if profitability slips, the stock could face pressure.
A DNA factory for drug builders
Twist makes money by using its silicon-based DNA synthesis platform to produce synthetic DNA at high scale. Customers buy genes, gene fragments, oligo pools, antibody discovery work, and sequencing workflow tools. The basic idea is simple: scientists design DNA on a computer, Twist builds it, and the customer uses it in research, diagnostics, or drug discovery.
The higher-value part of the model is moving customers from basic DNA orders into full workflows. AI drug discovery companies are a key example. Many of them need a fast loop: design a molecule, build the DNA, test the protein, learn from the result, then repeat. Twist can sell into several steps of that loop.
The model breaks if speed, quality, or cost advantage fades. It also breaks if newer demand is more one-time than repeat. That is why the mix of AI revenue matters. Recurring discovery work is much better than large model-building orders that do not repeat.
From genes to cancer panels
Synthetic genes and gene fragments
These are core DNA building blocks for research and drug discovery. They help fill Twist's platform and bring customers into the broader product set.
Oligo pools
Oligo pools are large sets of short DNA sequences used in experiments and screening. They support the high-throughput side of Twist's platform.
Protein solutions and antibody discovery
This area helps drug researchers move from DNA design to protein testing and antibody optimization. It is tied closely to AI-enabled drug discovery demand.
NGS applications
NGS means next-generation sequencing, a way to read many DNA fragments at once. Twist sells tools such as target enrichment panels for clinical and research workflows.
MRD Xpress
MRD Xpress is planned for individualized cancer monitoring panels. Management has said it can manufacture and ship tumor-informed panels in as little as 12 hours.
Complex DNA offering
This is a newer product area meant to serve harder DNA designs. The key open question is how much growth it can add and when it becomes broadly available.
Two engines, nearly even
Segment mix is from Q3 FY26, the quarter ended June 30, 2026. NGS applications accounted for 52%, while DNA synthesis and protein solutions accounted for 48% and grew much faster.
What could break the thesis
Breakeven slips again
High impact · Medium oddsTwist is targeting adjusted EBITDA breakeven in Q4 FY26. In Q3, gross margin compressed slightly to 52.8% due to customer mix. If revenue falls short or customer mix pressures margins further, those costs could push profitability farther out.
NGS recovery misses the target
High impact · Medium oddsManagement previously expected NGS applications to return to 20% growth by Q4 FY26. In Q3, it grew 12%. If the segment stalls, investors may question the recovery story.
AI orders prove lumpy
High impact · Medium oddsAI-enabled drug discovery is now a major part of the bull case. Management expects triple-digit order growth here. The open question is whether the revenue is recurring discovery work or large one-time orders.
MRD Xpress launches slowly
Medium impact · Medium oddsMRD Xpress is an important new NGS product for cancer monitoring expected in early 2026. The product sounds differentiated because Twist says it can ship individualized tumor-informed panels in 12 hours, but the revenue profile is still not clear.
Less diversification after data storage spinout
Medium impact · Low oddsTwist spun out its DNA data storage work into Atlas Data Storage in May 2025. The filing risk is that Twist may not receive all expected benefits if Atlas does not develop or commercialize the technology well.
In one breath
What does Twist Bioscience actually sell?
Twist sells synthetic DNA products, protein and antibody services, and tools used in next-generation sequencing. Its platform helps researchers and drug developers build and test biological designs faster.
Why is AI drug discovery important for Twist?
AI drug discovery companies need to test many designs in the lab. Twist can supply the DNA and related protein work that lets those companies run the design, build, test, learn cycle.
Is Twist Bioscience profitable?
The company is not yet built around steady GAAP profits. Management has guided for adjusted EBITDA breakeven in Q4 FY26, so the next few quarters are important.
What is the biggest thing to watch next?
Watch whether NGS applications return to 20% growth by Q4 FY26 and whether DNA synthesis keeps growing strongly. These signals will show whether the company can reach profitability.
